Charles Schwab Investment Management Inc. Has $260.43 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Charles Schwab Investment Management Inc. decreased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 515,479 shares of the company's stock after selling 4,770 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.63% of IDEXX Laboratories worth $260,430,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of IDXX. Eads & Heald Wealth Management boosted its stake in IDEXX Laboratories by 0.8% in the second quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company's stock worth $1,309,000 after purchasing an additional 22 shares in the last quarter. LRI Investments LLC grew its holdings in IDEXX Laboratories by 21.7% during the 2nd quarter. LRI Investments LLC now owns 129 shares of the company's stock worth $63,000 after acquiring an additional 23 shares during the last quarter. Sovereign Financial Group Inc. increased its position in IDEXX Laboratories by 5.1% in the 3rd quarter. Sovereign Financial Group Inc. now owns 470 shares of the company's stock valued at $237,000 after acquiring an additional 23 shares in the last quarter. Mather Group LLC. lifted its position in shares of IDEXX Laboratories by 3.9% during the third quarter. Mather Group LLC. now owns 617 shares of the company's stock worth $312,000 after purchasing an additional 23 shares in the last quarter. Finally, Angeles Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 2.4% during the third quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company's stock valued at $545,000 after purchasing an additional 25 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDXX has been the topic of several research reports. Barclays reduced their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. Piper Sandler reiterated a "neutral" rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. Finally, JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average price target of $552.38.

IDEXX Laboratories Stock Down 0.3 %

NASDAQ IDXX traded down $1.31 during trading hours on Friday, reaching $417.24. 503,442 shares of the company's stock were exchanged, compared to its average volume of 775,938. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company's 50-day moving average is $460.86 and its two-hundred day moving average is $480.70. The company has a market capitalization of $34.17 billion, a price-to-earnings ratio of 40.24, a price-to-earnings-growth ratio of 3.65 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm's quarterly revenue was up 6.6% on a year-over-year basis. During the same period last year, the business posted $2.53 earnings per share. On average, analysts forecast that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.